Mij
Senior Member (Voting Rights)
The direct-to-consumer medical testing industry is booming, with the global market predicted to reach more than US$9 billion by 2033. Genetic tests are increasingly available—with ten new ones entering the market every day—as well as biochemical tests for markers associated with health or disease, devices for monitoring parameters such as blood glucose, and even so-called wellness tests, all of which can be performed without a health professional involved. However, many screening tests sold to the public would not be conducted within a formal health system. Some have no medical purpose. Weak regulation has enabled the direct-to-consumer medical testing industry to flourish, but its growth is fueled by the exploitation of consumers’ fears and commercial interests that do not have our health at heart.
A recent Australian study found that, of several hundred direct-to-consumer tests evaluated, the vast majority had limited clinical utility, were non-evidence-based, or used methods or tested for conditions not recognized by the medical community. Companies advertise ‘‘fear nothing’’ and ‘‘free if we don’t find anything’’ tests. The likelihood is that most people will have at least one result that is outside the normal range when a panel of biomarkers are tested, and biomarker abnormality alone is not a disease.
Another emerging trend—the promotion of continuous glucose monitors to people without diabetes, with monthly subscriptions sold at great cost—lacks an evidence base and will create undue anxiety about diet. Medical testing should be grounded in evidence, not an opportunity to capitalise on the worried well.
LINK
A recent Australian study found that, of several hundred direct-to-consumer tests evaluated, the vast majority had limited clinical utility, were non-evidence-based, or used methods or tested for conditions not recognized by the medical community. Companies advertise ‘‘fear nothing’’ and ‘‘free if we don’t find anything’’ tests. The likelihood is that most people will have at least one result that is outside the normal range when a panel of biomarkers are tested, and biomarker abnormality alone is not a disease.
Another emerging trend—the promotion of continuous glucose monitors to people without diabetes, with monthly subscriptions sold at great cost—lacks an evidence base and will create undue anxiety about diet. Medical testing should be grounded in evidence, not an opportunity to capitalise on the worried well.
LINK